|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: TTC19 |
Gene summary for TTC19 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | TTC19 | Gene ID | 54902 |
| Gene name | tetratricopeptide repeat domain 19 | |
| Gene Alias | 2010204O13Rik | |
| Cytomap | 17p12 | |
| Gene Type | protein-coding | GO ID | GO:0000278 | UniProtAcc | Q6DKK2 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 54902 | TTC19 | HTA11_3410_2000001011 | Human | Colorectum | AD | 3.65e-12 | -4.45e-01 | 0.0155 |
| 54902 | TTC19 | HTA11_3361_2000001011 | Human | Colorectum | AD | 1.64e-03 | -4.21e-01 | -0.1207 |
| 54902 | TTC19 | HTA11_696_2000001011 | Human | Colorectum | AD | 4.88e-02 | -2.49e-01 | -0.1464 |
| 54902 | TTC19 | HTA11_866_3004761011 | Human | Colorectum | AD | 7.04e-03 | -2.73e-01 | 0.096 |
| 54902 | TTC19 | HTA11_10711_2000001011 | Human | Colorectum | AD | 4.76e-02 | -3.49e-01 | 0.0338 |
| 54902 | TTC19 | HTA11_7696_3000711011 | Human | Colorectum | AD | 3.01e-03 | -3.05e-01 | 0.0674 |
| 54902 | TTC19 | HTA11_99999971662_82457 | Human | Colorectum | MSS | 2.35e-04 | -3.41e-01 | 0.3859 |
| 54902 | TTC19 | HTA11_99999973899_84307 | Human | Colorectum | MSS | 9.19e-04 | -4.93e-01 | 0.2585 |
| 54902 | TTC19 | HTA11_99999974143_84620 | Human | Colorectum | MSS | 2.55e-06 | -3.63e-01 | 0.3005 |
| 54902 | TTC19 | A001-C-207 | Human | Colorectum | FAP | 1.31e-06 | -3.19e-01 | 0.1278 |
| 54902 | TTC19 | A015-C-203 | Human | Colorectum | FAP | 1.74e-27 | -4.88e-01 | -0.1294 |
| 54902 | TTC19 | A015-C-204 | Human | Colorectum | FAP | 2.31e-06 | -2.83e-01 | -0.0228 |
| 54902 | TTC19 | A014-C-040 | Human | Colorectum | FAP | 1.48e-05 | -4.34e-01 | -0.1184 |
| 54902 | TTC19 | A002-C-201 | Human | Colorectum | FAP | 7.24e-17 | -4.14e-01 | 0.0324 |
| 54902 | TTC19 | A002-C-203 | Human | Colorectum | FAP | 2.97e-03 | -1.78e-01 | 0.2786 |
| 54902 | TTC19 | A001-C-119 | Human | Colorectum | FAP | 2.81e-09 | -3.96e-01 | -0.1557 |
| 54902 | TTC19 | A001-C-108 | Human | Colorectum | FAP | 3.26e-14 | -2.35e-01 | -0.0272 |
| 54902 | TTC19 | A002-C-205 | Human | Colorectum | FAP | 8.85e-24 | -4.21e-01 | -0.1236 |
| 54902 | TTC19 | A001-C-104 | Human | Colorectum | FAP | 9.58e-03 | -1.64e-01 | 0.0184 |
| 54902 | TTC19 | A015-C-005 | Human | Colorectum | FAP | 1.47e-05 | -2.41e-01 | -0.0336 |
| Page: 1 2 3 4 5 6 7 8 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Colorectum (GSE201348) |  | FAP: Familial adenomatous polyposis |
| CRC: Colorectal cancer | ||
| Colorectum (HTA11) |  | AD: Adenomas |
| SER: Sessile serrated lesions | ||
| MSI-H: Microsatellite-high colorectal cancer | ||
| MSS: Microsatellite stable colorectal cancer | ||
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias | ||
| Lung |  | AAH: Atypical adenomatous hyperplasia |
| AIS: Adenocarcinoma in situ | ||
| IAC: Invasive lung adenocarcinoma | ||
| MIA: Minimally invasive adenocarcinoma | ||
| Oral Cavity |  | EOLP: Erosive Oral lichen planus |
| LP: leukoplakia | ||
| NEOLP: Non-erosive oral lichen planus | ||
| OSCC: Oral squamous cell carcinoma | ||
| Prostate |  | BPH: Benign Prostatic Hyperplasia |
| Skin |  | AK: Actinic keratosis |
| cSCC: Cutaneous squamous cell carcinoma | ||
| SCCIS:squamous cell carcinoma in situ | ||
| Thyroid |  | ATC: Anaplastic thyroid cancer |
| HT: Hashimoto's thyroiditis | ||
| PTC: Papillary thyroid cancer |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:0033108 | Colorectum | AD | mitochondrial respiratory chain complex assembly | 46/3918 | 93/18723 | 8.95e-10 | 6.91e-08 | 46 |
| GO:0000910 | Colorectum | AD | cytokinesis | 59/3918 | 173/18723 | 3.74e-05 | 6.75e-04 | 59 |
| GO:0061640 | Colorectum | AD | cytoskeleton-dependent cytokinesis | 37/3918 | 100/18723 | 1.58e-04 | 2.20e-03 | 37 |
| GO:0000281 | Colorectum | AD | mitotic cytokinesis | 25/3918 | 71/18723 | 3.77e-03 | 2.65e-02 | 25 |
| GO:00331082 | Colorectum | MSS | mitochondrial respiratory chain complex assembly | 44/3467 | 93/18723 | 2.17e-10 | 2.09e-08 | 44 |
| GO:00009102 | Colorectum | MSS | cytokinesis | 49/3467 | 173/18723 | 1.02e-03 | 1.02e-02 | 49 |
| GO:00002811 | Colorectum | MSS | mitotic cytokinesis | 23/3467 | 71/18723 | 3.55e-03 | 2.63e-02 | 23 |
| GO:00009103 | Colorectum | FAP | cytokinesis | 37/2622 | 173/18723 | 5.10e-03 | 3.37e-02 | 37 |
| GO:00009104 | Colorectum | CRC | cytokinesis | 34/2078 | 173/18723 | 6.47e-04 | 8.55e-03 | 34 |
| GO:0033108110 | Esophagus | ESCC | mitochondrial respiratory chain complex assembly | 83/8552 | 93/18723 | 9.56e-19 | 1.05e-16 | 83 |
| GO:000028115 | Esophagus | ESCC | mitotic cytokinesis | 58/8552 | 71/18723 | 4.34e-10 | 1.15e-08 | 58 |
| GO:001700413 | Esophagus | ESCC | cytochrome complex assembly | 34/8552 | 36/18723 | 5.08e-10 | 1.31e-08 | 34 |
| GO:000091016 | Esophagus | ESCC | cytokinesis | 115/8552 | 173/18723 | 2.48e-08 | 4.68e-07 | 115 |
| GO:006164015 | Esophagus | ESCC | cytoskeleton-dependent cytokinesis | 72/8552 | 100/18723 | 8.10e-08 | 1.39e-06 | 72 |
| GO:00009106 | Lung | IAC | cytokinesis | 31/2061 | 173/18723 | 4.28e-03 | 3.41e-02 | 31 |
| GO:003310818 | Oral cavity | OSCC | mitochondrial respiratory chain complex assembly | 75/7305 | 93/18723 | 2.17e-16 | 1.68e-14 | 75 |
| GO:00170043 | Oral cavity | OSCC | cytochrome complex assembly | 31/7305 | 36/18723 | 7.28e-09 | 1.53e-07 | 31 |
| GO:00002815 | Oral cavity | OSCC | mitotic cytokinesis | 51/7305 | 71/18723 | 2.01e-08 | 3.95e-07 | 51 |
| GO:000091010 | Oral cavity | OSCC | cytokinesis | 97/7305 | 173/18723 | 3.82e-06 | 4.51e-05 | 97 |
| GO:00616405 | Oral cavity | OSCC | cytoskeleton-dependent cytokinesis | 60/7305 | 100/18723 | 1.69e-05 | 1.67e-04 | 60 |
| Page: 1 2 3 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| TTC19 | SNV | Missense_Mutation | rs762239880 | c.724N>A | p.Ala242Thr | p.A242T | Q6DKK2 | protein_coding | tolerated(0.21) | benign(0.019) | TCGA-AN-A046-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| TTC19 | insertion | In_Frame_Ins | novel | c.743_744insATTGATGTGCGGACTCTTAATCTACTTAAAATGTGG | p.Leu248_Phe249insLeuMetCysGlyLeuLeuIleTyrLeuLysCysGly | p.L248_F249insLMCGLLIYLKCG | Q6DKK2 | protein_coding | TCGA-A8-A08H-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | ||
| TTC19 | SNV | Missense_Mutation | novel | c.628N>C | p.Glu210Gln | p.E210Q | Q6DKK2 | protein_coding | deleterious(0) | possibly_damaging(0.845) | TCGA-EA-A97N-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD |
| TTC19 | SNV | Missense_Mutation | c.445C>T | p.Arg149Trp | p.R149W | Q6DKK2 | protein_coding | deleterious(0) | possibly_damaging(0.875) | TCGA-AU-6004-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
| TTC19 | SNV | Missense_Mutation | rs749090956 | c.370N>T | p.Arg124Cys | p.R124C | Q6DKK2 | protein_coding | tolerated(0.11) | possibly_damaging(0.735) | TCGA-F5-6814-01 | Colorectum | rectum adenocarcinoma | Male | <65 | I/II | Unknown | Unknown | SD |
| TTC19 | SNV | Missense_Mutation | novel | c.673N>C | p.Ser225Pro | p.S225P | Q6DKK2 | protein_coding | tolerated(0.38) | benign(0.006) | TCGA-A5-A1OF-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| TTC19 | SNV | Missense_Mutation | c.1107N>T | p.Lys369Asn | p.K369N | Q6DKK2 | protein_coding | tolerated(0.19) | benign(0.03) | TCGA-A5-A2K5-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
| TTC19 | SNV | Missense_Mutation | rs759404597 | c.376N>A | p.Ala126Thr | p.A126T | Q6DKK2 | protein_coding | deleterious(0) | possibly_damaging(0.836) | TCGA-AJ-A3EL-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| TTC19 | SNV | Missense_Mutation | rs797046058 | c.478N>C | p.Lys160Gln | p.K160Q | Q6DKK2 | protein_coding | deleterious(0) | probably_damaging(0.959) | TCGA-AP-A1E0-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Chemotherapy | paclitaxel | SD |
| TTC19 | SNV | Missense_Mutation | rs749090956 | c.370N>T | p.Arg124Cys | p.R124C | Q6DKK2 | protein_coding | tolerated(0.11) | possibly_damaging(0.735) | TCGA-B5-A1MR-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | III/IV | Unknown | Unknown | SD |
| Page: 1 2 3 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |